SG11201803956UA - Anti-dr5 antibodies and methods of use thereof - Google Patents

Anti-dr5 antibodies and methods of use thereof

Info

Publication number
SG11201803956UA
SG11201803956UA SG11201803956UA SG11201803956UA SG11201803956UA SG 11201803956U A SG11201803956U A SG 11201803956UA SG 11201803956U A SG11201803956U A SG 11201803956UA SG 11201803956U A SG11201803956U A SG 11201803956UA SG 11201803956U A SG11201803956U A SG 11201803956UA
Authority
SG
Singapore
Prior art keywords
genmab
utrecht
international
yalelaan
drs
Prior art date
Application number
SG11201803956UA
Other languages
English (en)
Inventor
Marije Overdijk
Kristin Strumane
Rik Rademaker
Esther Breij
Janine Schuurman
Paul Parren
Original Assignee
Genmab Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab Bv filed Critical Genmab Bv
Publication of SG11201803956UA publication Critical patent/SG11201803956UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
SG11201803956UA 2015-12-01 2016-12-01 Anti-dr5 antibodies and methods of use thereof SG11201803956UA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DKPA201500771 2015-12-01
DKPA201500788 2015-12-07
DKPA201500787 2015-12-07
DKPA201600702 2016-11-10
DKPA201600701 2016-11-10
PCT/EP2016/079518 WO2017093448A1 (fr) 2015-12-01 2016-12-01 Anticorps anti-dr5 et procédés d'utilisation de ceux-ci

Publications (1)

Publication Number Publication Date
SG11201803956UA true SG11201803956UA (en) 2018-06-28

Family

ID=58796495

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201803956UA SG11201803956UA (en) 2015-12-01 2016-12-01 Anti-dr5 antibodies and methods of use thereof

Country Status (16)

Country Link
US (5) US20190202926A1 (fr)
EP (2) EP3383906A1 (fr)
JP (3) JP7254515B2 (fr)
KR (1) KR20180098567A (fr)
CN (2) CN109476737A (fr)
AU (2) AU2016363770A1 (fr)
BR (2) BR112018011100A2 (fr)
CA (2) CA3007031A1 (fr)
IL (1) IL259713A (fr)
MA (1) MA43365A (fr)
MX (1) MX2018006333A (fr)
NZ (1) NZ743316A (fr)
SG (1) SG11201803956UA (fr)
UA (1) UA126897C2 (fr)
WO (2) WO2017093447A1 (fr)
ZA (1) ZA201803079B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050171339A1 (en) * 2001-12-28 2005-08-04 Izumi Sugo Method of stabilizing protein
UA117901C2 (uk) * 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
WO2017093447A1 (fr) 2015-12-01 2017-06-08 Genmab B.V. Anticorps anti-récepteur de mort et procédés d'utilisation associés
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
US20180044430A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. FC Engineered Anti-TNFR Superfamily Member Antibodies Having Enhanced Atonistic Activity and Methods of Using Them
MA49259A (fr) * 2017-06-07 2020-04-15 Genmab Bv Anticorps thérapeutiques à base d'hexamères d'igg mutées
US20200283537A1 (en) * 2017-11-14 2020-09-10 University Of Virginia Patent Foundation Compositions and methods for making and using bispecific antibodies
CN109957020A (zh) * 2017-12-25 2019-07-02 深圳宾德生物技术有限公司 一种靶向dr5的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
EP3743440A1 (fr) 2018-01-24 2020-12-02 Genmab B.V. Variants polypeptidiques et leurs utilisations
SG11202010601VA (en) 2018-05-03 2020-11-27 Genmab Bv Antibody variant combinations and uses thereof
SG11202012993SA (en) * 2018-07-13 2021-02-25 Genmab As Variants of cd38 antibody and uses thereof
CN112638946A (zh) * 2018-08-16 2021-04-09 坎塔吉亚有限责任公司 抗il1rap抗体组合物
WO2020225456A1 (fr) 2019-05-09 2020-11-12 Genmab B.V. Schémas posologiques pour une combinaison d'anticorps anti-dr5 destinés à être utilisés dans le traitement du cancer
EP4055046A1 (fr) 2019-11-06 2022-09-14 Genmab B.V. Combinaisons de variants d'anticorps et leurs utilisations
EP4149553A1 (fr) * 2020-05-12 2023-03-22 IGM Biosciences Inc. Utilisation d'une molécule de liaison anti-dr5 multimère en association avec une thérapie anticancéreuse pour le traitement du cancer
CN111778333B (zh) * 2020-07-03 2022-11-18 东莞市滨海湾中心医院 测定edar表达水平的试剂的应用和试剂盒
WO2022018294A1 (fr) 2020-07-23 2022-01-27 Genmab B.V. Combinaison d'anticorps anti-dr5 et d'un médicament à base d'imide immunomodulateur à utiliser dans le traitement du myélome multiple
CN112915211B (zh) * 2021-02-07 2022-05-06 成都中医药大学 一种pd-l1靶向肽药物偶联物及其合成方法和应用
WO2023023677A1 (fr) * 2021-08-20 2023-02-23 University Of Virginia Patent Foundation Stratégie pour l'activation de dr5 hautement supérieure, notamment dans des tumeurs et des cancers

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284236B1 (en) 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
US6469144B1 (en) 1996-04-01 2002-10-22 Genentech, Inc. Apo-2LI and Apo-3 polypeptides
PT1012274E (pt) 1997-01-28 2007-08-14 Craig A Rosen Receptor 4 contendo um domínio de morte (dm4; receptor de morte 4), membro da super-família do ftn e ligação a liart (ap02)
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US20050233958A1 (en) 1997-03-17 2005-10-20 Human Genome Sciences, Inc. Death domain containing receptor 5
WO1999036535A1 (fr) 1998-01-15 1999-07-22 Genentech, Inc. Apo-2 ligand
ES2267547T3 (es) 1999-06-09 2007-03-16 Genentech, Inc. Sinergia de antagonista de receptores del ligando apo-2l y de cpt-11.
US6444640B1 (en) 1999-09-30 2002-09-03 Ludwig Institute For Cancer Research Compositions of trail and DNA damaging drugs and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
US20020155109A1 (en) 2001-04-20 2002-10-24 Lynch David H. Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2
AU2002309647C1 (en) 2001-05-25 2008-09-11 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
ES2328234T3 (es) 2001-07-03 2009-11-11 Genentech, Inc. Anticuerpos dr4 humanos y utilizaciones de los mismos.
KR20070010046A (ko) 2004-04-06 2007-01-19 제넨테크, 인크. Ｄｒ5 항체 및 그의 용도
EP2213683B1 (fr) * 2004-08-04 2013-06-05 Mentrik Biotech, LLC Régions Fc variantes
PE20071101A1 (es) * 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
KR100847010B1 (ko) 2006-07-05 2008-07-17 아주대학교산학협력단 세포사멸 수용체 5 (ｄｒ5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물
TW200904072A (en) 2007-07-05 2009-01-16 Ic Plus Corp System and method for generating interrupt
WO2010003766A2 (fr) 2008-06-17 2010-01-14 Apogenix Gmbh Récepteurs multimériques tnf
EP2166021A1 (fr) * 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Anticorps monoclonaux pour le traitement du cancer
CN103339145A (zh) * 2010-09-22 2013-10-02 安姆根有限公司 运载体免疫球蛋白及其用途
ES2675847T3 (es) * 2010-10-29 2018-07-13 Daiichi Sankyo Company, Limited Nuevo anticuerpo anti-DR5
UA117901C2 (uk) * 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
BR112015000167B1 (pt) 2012-07-06 2021-11-23 Genmab B.V. Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
EP2684896A1 (fr) * 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anticorps de la famille anti-DR5 ou bispécifique anticorps de la famille anti-DR5 multivalents et leurs procédés d'utilisation
EP2943506B1 (fr) * 2013-01-10 2024-03-13 Genmab B.V. Variantes de la région fc d'igg1 humaine et leurs utilisations
WO2017093447A1 (fr) 2015-12-01 2017-06-08 Genmab B.V. Anticorps anti-récepteur de mort et procédés d'utilisation associés
MA46700A (fr) 2016-11-01 2021-05-19 Genmab Bv Variants polypeptidiques et ses utilisations
AU2018218345A1 (en) 2017-02-10 2019-08-29 Genmab B.V. Polypeptide variants and uses thereof

Also Published As

Publication number Publication date
US10882913B2 (en) 2021-01-05
BR112018011100A2 (pt) 2018-12-04
US20220411522A1 (en) 2022-12-29
US20190144554A1 (en) 2019-05-16
AU2016363770A1 (en) 2018-06-28
AU2024200261A1 (en) 2024-02-01
JP2019501151A (ja) 2019-01-17
CN108884158A (zh) 2018-11-23
UA126897C2 (uk) 2023-02-22
BR112018011058A2 (pt) 2018-11-21
ZA201803079B (en) 2023-12-20
WO2017093447A1 (fr) 2017-06-08
CA3007033A1 (fr) 2017-06-08
JP2023022186A (ja) 2023-02-14
IL259713A (en) 2018-07-31
CA3007031A1 (fr) 2017-06-08
US20190202926A1 (en) 2019-07-04
CN109476737A (zh) 2019-03-15
MX2018006333A (es) 2018-08-01
WO2017093448A1 (fr) 2017-06-08
JP2019500869A (ja) 2019-01-17
EP3383905A1 (fr) 2018-10-10
KR20180098567A (ko) 2018-09-04
MA43365A (fr) 2018-10-10
JP7254515B2 (ja) 2023-04-10
US20210324096A1 (en) 2021-10-21
NZ743316A (en) 2023-12-22
EP3383906A1 (fr) 2018-10-10
US20190315877A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
SG11201803956UA (en) Anti-dr5 antibodies and methods of use thereof
SG11201909941QA (en) Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201810883TA (en) Combination therapy
SG11201907753TA (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201804839WA (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
SG11201805870YA (en) Bispecific t cell engaging antibody constructs
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201807437XA (en) Antibodies specific to human poliovirus receptor (pvr)
SG11201809336QA (en) Anti-pd-l1 antibodies
SG11201807489PA (en) Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
SG11201900955VA (en) T cell receptors and immune therapy using the same
SG11201808979UA (en) Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
SG11201805770UA (en) BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs
SG11201909081YA (en) Anti-ilt4 antibodies and antigen-binding fragments
SG11201810640RA (en) Cd33 specific chimeric antigen receptors
SG11201905699XA (en) Anti-icos agonist antibodies and uses thereof
SG11201806150RA (en) Psma and cd3 bispecific t cell engaging antibody constructs
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201910134SA (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201806261XA (en) Bcma antibodies and use of same to treat cancer and immunological disorders
SG11201907580SA (en) Combination therapies for treatment of bcma-related cancers and autoimmune disorders
SG11201900885VA (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
SG11201809879WA (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201408780XA (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
SG11201804178YA (en) Pd1 and/or lag3 binders